See the DrugPatentWatch profile for Delstrigo
Delstrigo vs. Atripla: What's the difference?
Delstrigo and Atripla are both single-tablet regimens used to treat HIV infection, but they contain different active ingredients. Delstrigo combines doravirine, lamivudine, and tenofovir disoproxil fumarate. Atripla contains efavirenz, emtricitabine, and tenofovir disoproxil fumarate. The choice between them depends on individual patient factors, including medical history and potential drug interactions.
What are the active ingredients in Delstrigo?
Delstrigo is a combination antiretroviral medication that includes three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate [1]. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) [1].
What are the active ingredients in Atripla?
Atripla is a single-tablet regimen for HIV treatment that contains efavirenz, emtricitabine, and tenofovir disoproxil fumarate [2]. Efavirenz is an NNRTI, and emtricitabine and tenofovir disoproxil fumarate are NRTIs [2].
How do Delstrigo and Atripla compare in terms of effectiveness?
Both Delstrigo and Atripla are considered effective in suppressing viral load in individuals with HIV. Clinical trials have shown comparable efficacy between regimens containing doravirine (as in Delstrigo) and regimens containing efavirenz (as in Atripla) [1][2]. However, doravirine has demonstrated a lower rate of treatment discontinuation due to adverse events compared to efavirenz in some studies [1].
What are the side effects of Delstrigo?
Common side effects associated with Delstrigo include dizziness, nausea, diarrhea, headache, and fatigue [1]. Some individuals may experience abnormal dreams or insomnia. The side effect profile can vary among patients.
What are the side effects of Atripla?
Atripla is known to cause a range of central nervous system side effects, such as dizziness, abnormal dreams, insomnia, and mood changes [2]. Other potential side effects include rash, nausea, and diarrhea. The efavirenz component in Atripla is particularly associated with these neuropsychiatric effects.
Are there differences in drug interactions between Delstrigo and Atripla?
Both Delstrigo and Atripla can have drug interactions with other medications. However, the specific interactions may differ due to their distinct active ingredients [1][2]. It is crucial for patients to disclose all medications they are taking to their healthcare provider to avoid potentially harmful interactions. For instance, doravirine (in Delstrigo) has fewer interactions with certain medications compared to efavirenz (in Atripla) [1].
When does patent exclusivity expire for Delstrigo and Atripla?
Information regarding the patent expiry dates for Delstrigo and Atripla can be found on DrugPatentWatch.com [3]. Patent expiry allows for the potential introduction of generic versions of these medications, which could impact pricing and accessibility.
What are the generic options for Delstrigo and Atripla?
As of now, specific generic versions of Delstrigo may not be widely available, and similarly, generic Atripla has been subject to market changes. The development of generics depends on patent expiry and regulatory approvals. Information on available generics and their respective patent statuses can be accessed through resources like DrugPatentWatch.com [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/delstrigo
[2] https://www.drugpatentwatch.com/drug/atripla
[3] https://www.drugpatentwatch.com